Crizotinib May Provide Disease Control in Advanced Papillary Renal Cell Carcinoma
Patients with advanced papillary renal cell carcinoma type 1 with mesenchymal-epithelial transition factor (MET) mutations achieved disease control with the tyrosine kinase inhibitor crizotinib. The results of the EORTC 90101 CREATE study, authored by Patrick Schöffski, MD, MPH, of the Leuven Cancer Institute in Belgium, and colleagues, were published in the European Journal of Cancer.
The phase II trial evaluated the efficacy and safety of crizotinib in 23 patients with papillary renal cell carcinoma type 1 with or without the MET mutation. Four patients had MET-positive disease. All 23 patients received oral crizotinib at 250 mg twice daily.
Analysis showed an objective response rate of 50% in the MET-positive group. In patients with MET-negative disease, an objective response rate of 6.3% was observed. The most frequent adverse events noted were edema, fatigue, nausea, diarrhea, and blurred vision.